MOG and myeloid sarcoma: The results described here indicate that a patented peptide TnP presents as valuable potential first leader candidate to design a new drug to demyelinating conditions as MS, once ameliorated the severity of the clinical signs of MOG-induced EAE, accompanied by inhibition of neuroinflammation and improvement of the remyelination.